• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.

作者信息

Guidez Stephanie, Lacotte-Thierry Laurence, Tomowiak Cecile, Princet Isabelle, Dreyfus Brigitte, Olivier Gaelle, Fleck Emmanuel, Corby Anne, Motard Carine, Barrier Jocelyn, Machet Antoine, Le Dû Katell, Debiais-Delpech Celine, Chabin Michele, Leleu Xavier, Guilhot Joëlle, Delwail Vincent

机构信息

Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.

INSERM CIC 1402, CHU, Poitiers, France.

出版信息

Br J Haematol. 2019 Sep;186(6):e175-e178. doi: 10.1111/bjh.16056. Epub 2019 Jul 15.

DOI:10.1111/bjh.16056
PMID:31309541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6772118/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b409/6772118/f5e33e9c5044/BJH-186-e175-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b409/6772118/f5e33e9c5044/BJH-186-e175-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b409/6772118/f5e33e9c5044/BJH-186-e175-g001.jpg

相似文献

1
Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.60至80岁弥漫性大B细胞淋巴瘤患者的口服类CHOP化疗方案
Br J Haematol. 2019 Sep;186(6):e175-e178. doi: 10.1111/bjh.16056. Epub 2019 Jul 15.
2
Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤的代谢肿瘤体积与治疗反应
Hematol Oncol. 2019 Aug;37(3):308-309. doi: 10.1002/hon.2612. Epub 2019 Apr 26.
3
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.一项针对连续入选的、未经筛选的老年初发弥漫性大B细胞淋巴瘤患者队列，对R-CHOP计划剂量强度对预后影响的大型回顾性分析结果。
Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29.
4
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Important Adv Oncol. 1990:217-25.
5
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.初治中高危弥漫大 B 细胞淋巴瘤患者口服阿扎胞苷（CC-486）联合 R-CHOP 的 I 期研究。
Blood. 2022 Feb 24;139(8):1147-1159. doi: 10.1182/blood.2021011679.
6
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).依维莫司联合RCHOP方案治疗初治弥漫性大B细胞淋巴瘤24个月时无事件生存率高：NCCTG N1085（联盟）的更新结果
Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57.
7
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
8
A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.老年弥漫性大B细胞淋巴瘤患者的宿主依赖性预后模型
Oncologist. 2017 May;22(5):554-560. doi: 10.1634/theoncologist.2016-0260. Epub 2017 Apr 13.
9
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.80 岁以上弥漫性大 B 细胞淋巴瘤患者的减毒免疫化疗方案（R-miniCHOP）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7.
10
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.CNS 国际预后指数：R-CHOP 治疗弥漫性大 B 细胞淋巴瘤患者 CNS 复发的风险模型。
J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.

本文引用的文献

1
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.与标准CHOEP - 14方案相比，伊达比星在侵袭性非霍奇金淋巴瘤治疗中显著增加剂量会导致血液毒性增加且疗效未改善：DSHNHL的CIVEP试验9年随访结果
Springerplus. 2014 Jan 3;3:5. doi: 10.1186/2193-1801-3-5.
2
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
3
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.与标准利妥昔单抗 CHOP 相比，密集剂量利妥昔单抗 CHOP 治疗老年弥漫性大 B 细胞淋巴瘤患者（LNH03-6B 研究）：一项随机 3 期试验。
Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9.
4
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.环磷酰胺、多柔比星、长春新碱、泼尼松和利妥昔单抗与表柔比星、环磷酰胺、长春碱、泼尼松和利妥昔单抗用于初治老年“适合”弥漫性大 B 细胞淋巴瘤患者：意大利淋巴瘤研究组的 ANZINTER3 试验结果。
Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.
5
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).老年侵袭性CD20+B细胞淋巴瘤患者接受每两周一次的CHOP-14方案化疗6周期与8周期并联合或不联合利妥昔单抗的疗效比较：一项随机对照试验（RICOVER-60）
Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.
6
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.利妥昔单抗联合CHOP方案与单纯CHOP方案或CHOP方案联合利妥昔单抗维持治疗老年弥漫性大B细胞淋巴瘤的比较。
J Clin Oncol. 2006 Jul 1;24(19):3121-7. doi: 10.1200/JCO.2005.05.1003. Epub 2006 Jun 5.
7
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
8
Penetration of idarubicin into malignant brain tumor tissue.伊达比星在恶性脑肿瘤组织中的渗透情况。
J Neurooncol. 1999 Aug;44(1):65-9. doi: 10.1023/a:1006335517191.
9
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.非霍奇金淋巴瘤反应标准规范化国际研讨会报告。美国国立癌症研究所赞助的国际工作组。
J Clin Oncol. 1999 Apr;17(4):1244. doi: 10.1200/JCO.1999.17.4.1244.
10
Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.蒽环类药物及其C-13醇代谢物：与培养的人肿瘤细胞孵育后的生长抑制和DNA损伤
Cancer Chemother Pharmacol. 1992;30(1):51-7. doi: 10.1007/BF00686485.